As shown in Table 5, currently available IL-4-, IL-5-, and IL-13-targeted therapies underscore the translational gap between the established indication in allergic diseases and the lack of clinical evidence in obesity. This evidence concerns the gene IL5 and obesity due to melanocortin 4 receptor deficiency.